Results 221 to 230 of about 471,442 (349)

Investigating Variations in Medicine Approvals for Attention-Deficit/Hyperactivity Disorder: A Cross-Country Document Analysis Comparing Drug Labeling. [PDF]

J Atten Disord
Tanana L, Latif A, Nishtala PS, Chen TF.
europepmc   +1 more source

Paediatric cardiovascular clinical trials: an analysis of ClinicalTrials.gov and the Food and Drug Administration Pediatric Drug Labeling Database. [PDF]

Cardiol Young, 2015
Hill KD, Henderson HT, Hornik CP, Li JS.
europepmc   +1 more source

Management and Outcomes in Confirmed or Suspected Acute Symptomatic Seizure: Role of Structured Outpatient Care

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Post‐discharge management and outcomes of acute symptomatic seizures (ASyS) remain underexplored. We analyzed post‐discharge ASM management and outcomes in ASyS patients undergoing continuous EEG (cEEG), including the role of outpatient care through a post‐acute symptomatic seizure (PASS) clinic. Methods We performed a single‐center,
Vineet Punia, MarieElena Byrnes, Nicolas R. Thompson, Neishay Ayub, Clio Rubinos, Sahar Zafar, Adithya Sivaraju, Zhong Ying, Jessica R. Fesler, Stephen Hantus, Post‐Acute Symptomatic Seizure Investigation and Outcomes Network (PASSION) investigators   +10 more
wiley   +1 more source

Doctors’ Confusion over Ratios and Percentages in Drug Solutions: The Case for Standard Labelling [PDF]

, 2004
Daniel W. Wheeler, Dionysios-Dennis Remoundos, Kim Whittlestone, M PALMER, S. J. Wheeler, T. R. Ringrose, David Krishna Menon   +6 more
openalex   +1 more source

Reconstitution of CXCR3+ CCR6+ Th17.1‐Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Objectives Ofatumumab, a fully human anti‐CD20 monoclonal antibody, is effective in reducing relapses and disability progression in patients with multiple sclerosis. This study aimed to examine immune profile changes associated with ofatumumab in a prospective cohort of Chinese patients with relapsing–remitting multiple ...
Shu Yang, Tian‐Xiang Zhang, Jia Liu, Zhirui Liu, Lijie Zhu, Yan‐Yan Li, Bin Feng, Moli Fan, Fu‐Dong Shi, Chao Zhang   +9 more
wiley   +1 more source

Why the Food and Drug Administration Changed the Warning Label for Hetastarch [PDF]

, 2004
Gary R. Haynes, Jeana E. Havidich, Kim Payne   +2 more
openalex   +1 more source

Very High‐Frequency Oscillations in Mesial Temporal Lobe Epilepsy: Identifying the Epileptogenic Zone

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate the reliability of very high‐frequency oscillations (VHFOs, 500–2000 Hz) as biomarkers in identifying the epileptogenic zone (EZ) in mesial temporal lobe epilepsy (MTLE) patients. Methods We reviewed 19 MTLE patients who underwent stereo‐electroencephalography‐guided radiofrequency thermocoagulation.
Stéphane Jean, Yihai Dai, Yan Cui, Donghuo Deng, Zhe Qian, Panashe Tevin Tagu, Weitao Chen, Weihong Liu, Xiaoqiang Wei, Xinrong Fang, Shiwei Song   +10 more
wiley   +1 more source

Regulation of Prescription Drug Advertising: Medical Progress and Private Enterprise [PDF]

, 1967
Ruge, Richard B.
core   +2 more sources

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib, Kristl G. Claeys, Vera Bril, Yessar Hussain, Kelly Gwathmey, Gregory Sahagian, Elena Cortés‐Vicente, Edward Brauer, Deborah Gelinas, Anne Sumbul, Rosa H. Jimenez, Daniela Hristova, Delphine Masschaele, Renato Mantegazza, Andreas Meisel, Shahram Attarian, On behalf of the ADAPT NXT Study Group   +16 more
wiley   +1 more source

Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐Label, Phase 1 Trial

Arthritis Care &Research, EarlyView.
Objective This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods In an open‐label, phase 1 study (SELECT‐YOUTH), enrolled patients, aged 2 to <18 years with pcJIA, received body weight–based ...
Hermine I. Brunner, Anna Shmagel, Gerd Horneff, Ivan Foeldvari, Jordi Antón, Athimalaipet V. Ramanan, Yuli Qian, Kristina Unnebrink, Shuai Hao, Heidi S. Camp, Nasser Khan, Wei Liu, Mohamed‐Eslam F. Mohamed   +12 more
wiley   +1 more source